LS patients carrying a germline mutation in one of the MMR genes, typically MLH1, MSH2, or EPCAM deletion, have a lifetime CRC risk of 41–80% and endometrial cancer risk of 40–60%, with median age of onset in the 40s2–5. This evidence concerns the gene MLH1 and Leigh syndrome.